Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) — Cash Flow Quality Index

Latest as of March 2026: -0.02x

Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a Cash Flow Quality Index of -0.02x as of March 2026. Operating cash flow of $-102.50K is below net income of $4.34 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore DMII cash flow metrics to assess how effectively this company generates cash.

Cash Flow Quality Index

-0.02x
Operating CF / Net Income

Operating Cash Flow

$-102.50K
USD

Net Income

$4.34 Million
USD

Data as of

Mar 2026
Most recent filing

Drugs Made In America Acquisition II Corp. Ordinary Shares Cash Flow Quality Index (2025–2025)

Historical Cash Flow Quality Index for Drugs Made In America Acquisition II Corp. Ordinary Shares across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore DMII debt coverage from operations to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Quality Index for Drugs Made In America Acquisition II Corp. Ordinary Shares (2025–2025)

Year-by-year earnings quality comparison for Drugs Made In America Acquisition II Corp. Ordinary Shares. For live market cap and the full company financial profile, see Drugs Made In America Acquisition II Cor (DMII) total market value.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 -0.24x $-1.02 Million $4.19 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.